A multi-centre study to compare and evaluate a herbal capsule in patients with hemorrhoids

A multi-centric, randomised, comparative, clinical study for evaluation of herbal capsule in patients suffering from hemorrhoids - HILO

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2017/10/010038

Enrollment

120

Registered

2017-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K649- Unspecified hemorrhoids

Interventions

Intervention1: Herbal Capsule (HILO) : Fixed dose combination Commiphora molmol 250 mg Gardenia gummifera 83 mg Tagetes erecta 83.5 mg Mesua ferrea

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either gender, aged >=18 years, with hemorrhoids confirmed by proctoscopy 2.Patients able to give signed informed consent before examination.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to any of the ingredients of the formulation 2.Patients currently using other antihemorrhoidal drugs or planning to undergo any surgical procedure for hemorrhoids 3.Pregnant women, or lactating mothers 4.Patients otherwise judged to be inappropriate for inclusion in the study by the investigator

Design outcomes

Primary

Measure	Time frame
Assess the efficacy of herbal capsules (HILO) compared to Daflon in patients with Hemorrhoids.Timepoint: Proportion of patients showing improvement in clinical symptoms	—

Secondary

Measure	Time frame
To evaluate the safety of the investigational product in Indian patients Timepoint: Proportion of patients reporting adverse events	—

Countries

India

Contacts

Public ContactDr Bhupesh Dewan

Zuventus Healthcare Limited

bhupesh.dewan@zuventus.com022-30610000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026